grant

Advancing the development of tools to better understand humoral responses to sapovirus following natural infections

Organization UNIV OF NORTH CAROLINA CHAPEL HILLLocation CHAPEL HILL, UNITED STATESPosted 8 Sept 2025Deadline 31 Aug 2027
NIHUS FederalResearch GrantFY20250-11 years old0-4 weeks old21+ years old7S Gamma GlobulinAcuteAdultAdult HumanAdvanced DevelopmentAge MonthsAntibodiesAntibody ResponseAntigensAssayBindingBioassayBiological AssayBirthBlood SerumBreast FeedingBreast MilkBreast fedBreastfedBreastfeedingBreastmilkCaliciviridaeCalicivirusCell Culture SystemCell Culture TechniquesCharacteristicsChildChild YouthChildhoodChildren (0-21)ClinicalCohort StudiesCollaborationsCommunitiesConcurrent StudiesDataDevelopmentDiarrheaDoseEnzyme ImmunoassayEnzyme Linked Immunoassay ImmunologicEpidemiologic ResearchEpidemiologic StudiesEpidemiological StudiesEpidemiologyEpidemiology ResearchFamilyFecesFundingGastroenteritisGenotypeHumanHuman MilkHuman Mother's MilkHumoral ImmunitiesIgAIgGImmunityImmunochemical ImmunologicImmunoglobulin AImmunoglobulin GImmunologicImmunologicalImmunologicallyImmunologicsImmunologyIncidenceInfectionInfection preventionInnate ImmunityIntestinal MucosaKineticsKnowledgeLaboratoriesLifeMammary Gland MilkManuscriptsMeasuresMethodsModern ManMolecular InteractionMother's MilkMothersMucosaMucosal TissueMucous MembraneNational Institutes of HealthNative ImmunityNatural HistoryNatural ImmunityNatureNewborn InfantNewbornsNicaraguaNon-Specific ImmunityNonspecific ImmunityNorovirusNorwalk-like VirusesParturitionPrevent infectionProductionReagentRotavirusSalivaSamplingSapovirusSapporo-like VirusesSerumSiteTechniquesTestingTimeUnited States National Institutes of HealthUniversitiesVaccinesVirusVirus-like particleadulthoodadvanced analyticsanalytical toolantibody-based immunitybiobankbiorepositoryburden of diseaseburden of illnesscell culturecell culturescognitive developmentcohortdevelop a vaccinedevelop vaccinesdevelopment of a vaccinedevelopmentaldisease burdenenteral pathogenenteric pathogenenteropathogenepidemiologicepidemiologic investigationepidemiologicalepidemiology studyexperiencefecal sampleimmunogeninsightintestinal pathogenintestine pathogenkidsmaternal milkneutralizing antibodynewborn childnewborn childrennovel viruspediatricphase 3 trialphase III trialpreventpreventingresponsestoolstool samplestool specimentooltool developmentvaccine developmentvirus-like nanoparticlesviruslike particleyoungster
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

ABSTRACT
Sapovirus (SaV), a genus in the Caliciviridae family alongside norovirus, is increasingly recognized as an

important cause of acute gastroenteritis (AGE) in childhood. SaV ranked second among all enteric pathogens in

its contribution to AGE incidence in children under 24 months of age in a large multi-site birth cohort study. While

vaccines against rotavirus have lowered the burden of childhood AGE and a pediatric norovirus vaccine is in

Phase III trials, currently, there are no vaccines against SaV. A major challenge to SaV vaccine development is

that there is little known about natural immunity to serve as a guide for vaccine-elicited immunity, including what

levels and types of antibodies (Abs) protect against infection. This may be due to the fact that human SaVs are

not readily grown in cell culture, hindering infectivity studies and antigen production. Dr. Nordgren at Linköping

University has recently implemented SaV cultivation in his lab and has provided as proof of concept that

convalescent sera can protect against SaV infection. Our team is uniquely poised to substantially advance the

understanding of natural neutralizing immunity to sapovirus with our biobank from field epidemiology research

in Nicaragua and state-of-the-art laboratory techniques to measure neutralizing Abs. Leveraging an NIH-funded

birth cohort of 444 children in León, Nicaragua, this project aims to characterize the kinetics of neutralizing Abs

to SaV in longitudinal serum and stool samples collected from 50 children experiencing a SaV gastroenteritis

episode during the first two years of life. In addition, we will test whether polyclonal sera neutralize homotypic

and heterotypic SaV, and compare neutralizing Ab levels between children who do and do not develop SaV AGE

episodes. We will also determine the correlation between neutralizing Ab levels and levels of IgG and IgA as

determined by enzyme immunoassays (EIAs). Together, this unique collaboration and sample set allows us to

advance analytic tools to better understand the immunology of sapovirus in children. Most importantly, this

project will generate a new tool that will be shared with the scientific community and is fundamental for the

understanding of natural humoral immunity to SaV.

Grant Number: 1R21AI190832-01
NIH Institute/Center: NIH

Principal Investigator: Sylvia Becker-Dreps

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →